Details of the Drug

General Information of Drug (ID: DM87XVD)

Drug Name

ET140202

Indication

Disease Entry	ICD 11	Status	REF
Hepatocellular carcinoma	2C12.02	Phase 1	[1]
Liver cancer	2C12	Phase 1	[2]
------------------------------------------------------------------------------------

Drug Type

CAR-T cell therapy

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT03998033) An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140202 T Cells and Determine the Recommended Phase II Dose ("RP2D") in Adults With Advanced Hepatocellular Carcinoma ("HCC"). U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT03965546) Clinical Study of ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Advanced Liver Cancer. U.S.National Institutes of Health.